Quick answer
A team led by researcher Hu Fanlei in the rheumatology and immunology department of Peking University People's Hospital has developed a high-sensitivity, minimally-invasive test card for rheumatoid arthritis. It uses a finger-prick (peripheral) blood sample, needs no venous draw or large lab equipment, and reports a result in about 15 minutes — aiming to solve the problem of missed diagnosis in seronegative RA [1][2].
Key takeaways
- RA is frequently missed: roughly one-third of patients have none of the standard diagnostic blood markers (seronegative RA), so diagnosis is delayed and disability can follow [1].
- The card detects multiple indicators together, via six patented technologies, to catch seronegative RA [2].
- It uses a minimally-invasive finger-prick sample — no venous blood draw, no large instruments; low cost and simple to run [1][2].
- Reported sensitivity is close to 90%, with a result in about 15 minutes versus roughly 3–4 hours for a conventional blood test [2].
- The device is at sample stage and not yet an approved, on-market product; the team hopes it will strengthen grassroots and early screening [2].
The problem it addresses
Rheumatoid arthritis is diagnosed partly from blood markers such as rheumatoid factor and anti-CCP antibodies. But a substantial minority of patients are "seronegative" — those markers are absent — so their disease goes undetected until joint damage is advanced. Because of this, a large share of RA patients are diagnosed late, a key barrier to early, effective treatment [1][2].
The card concentrates multi-indicator laboratory detection onto a small card. By combining signals instead of relying on a single marker, it aims to detect RA — including seronegative cases — from a drop of fingertip blood [1][2].
What was shown
The device was displayed at the 2026 China International Fair for Trade in Services (CIFTIS) in Beijing in September 2026, where staff reported diagnostic sensitivity close to 90% and a roughly 15-minute turnaround, far faster than conventional blood testing. It is described as suitable for grassroots screening, clinical diagnosis and disease monitoring [1][2].
By the team's own account the card is at sample stage. Sensitivity figures come from exhibitor statements, not peer-reviewed clinical trials, and the device still needs validation and regulatory approval before it becomes a routine test [2].
The condition in context: rheumatoid arthritis
Rheumatoid arthritis is a chronic autoimmune disease that inflames the joints, causing pain, swelling and, untreated, joint damage and disability. It is one of the most common autoimmune conditions and affects women far more often than men [4][5].
| Region | What the data shows | Source |
|---|---|---|
| Worldwide | Musculoskeletal conditions affect about 1.71 billion people; rheumatoid arthritis is a leading autoimmune cause of disability [5]. | World Health Organization [5] |
| General | RA affects roughly 0.5–1% of adults and is markedly more common in women [4]. | American College of Rheumatology [4] |
| Diagnostic gap | About one-third of RA patients are seronegative, so standard blood tests miss them, delaying treatment [1][2]. | Peking University People's Hospital [1][2] |
Earlier, simpler diagnosis — especially in primary care — could shorten the delay to treatment that drives long-term disability [1][2].
Why it matters
| For the patient | What the report suggests | Source |
|---|---|---|
| Earlier detection | Multi-indicator detection may catch seronegative RA that single markers miss [1][2]. | [1][2] |
| Access | Finger-prick, 15-minute, low-cost format could bring RA testing to grassroots and point-of-care settings [2]. | [2] |
| Caution | It is a sample-stage device; sensitivity figures need independent validation and approval before routine use [2]. | [2] |
Availability and limits
- This is an editorial summary of hospital, trade-fair and media reports, not an independent clinical assessment or a booking channel [1][2][3].
- The card is at sample stage and is not an approved, commercially available diagnostic [2].
- Sensitivity (~90%) and timing (15 minutes) are exhibitor-reported and have not been confirmed in peer-reviewed trials [2].
- RA diagnosis still depends on a clinician's full assessment; a screening card would support, not replace, that [1].
- Epidemiology figures describe rheumatoid arthritis generally and come from the ACR and WHO, not from this device [4][5].
What to ask before booking
| Question | Why it matters |
|---|---|
| Could my joint symptoms be seronegative RA? | Standard blood markers can be normal; a rheumatologist's assessment matters [1][2]. |
| Which tests are currently used to diagnose me? | The new card is not yet on the market; current RA testing uses blood markers plus clinical review [2]. |
| Which department handles foreign patients, and in what language? | PKUPH is a working hospital we do not book; confirm international-department coordination and language support. |
| How are visits, tests and follow-up scheduled around travel? | Autoimmune assessment involves several visits and tests; plan travel accordingly. |
Questions patients ask
What is the new RA test card?
A high-sensitivity, minimally-invasive card developed by Hu Fanlei's team at Peking University People's Hospital. It detects multiple indicators from a finger-prick blood sample and reports a result in about 15 minutes [1][2].
Why does RA get missed?
About one-third of RA patients are seronegative — they lack the usual rheumatoid factor or anti-CCP antibodies — so standard blood tests miss them and diagnosis is delayed until joint damage is advanced [1].
How accurate and fast is it?
Exhibitors at the 2026 CIFTIS reported diagnostic sensitivity close to 90% and a roughly 15-minute result, versus about 3–4 hours for conventional blood testing. These figures come from the team's statements and still need independent validation [2].
Is the card available now?
Not yet. The team describes it as being at sample stage; it still needs clinical validation and regulatory approval before becoming a routine test [2].
Is this relevant to international patients considering care in China?
It is useful context for China's diagnostic innovation in rheumatology. PKUPH is a working hospital we do not book — for RA assessment, contact its international department directly and confirm language support and logistics [1][2].